Construction of Risk Prediction Model of Type 2 Diabetic Kidney Disease Based on Deep Learning
CONCLUSION: The developed DKD risk predictive model using LSTM neural networks demonstrated high accuracy and AUC value. When HbA1c, SBP, and PP variabilities were added to the model as featured characteristics, the model's performance was greatly improved.PMID:38685670 | DOI:10.4093/dmj.2023.0033 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 30, 2024 Category: Endocrinology Authors: Chuan Yun Fangli Tang Zhenxiu Gao Wenjun Wang Fang Bai Joshua D Miller Huanhuan Liu Yaujiunn Lee Qingqing Lou Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
This article reviews the recent research progress of GLP-1 in lipid metabolism.PMID:38650100 | DOI:10.4093/dmj.2023.0277 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Tong Bu Ziyan Sun Yi Pan Xia Deng Guoyue Yuan Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
This article reviews the recent research progress of GLP-1 in lipid metabolism.PMID:38650100 | DOI:10.4093/dmj.2023.0277 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Tong Bu Ziyan Sun Yi Pan Xia Deng Guoyue Yuan Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
This article reviews the recent research progress of GLP-1 in lipid metabolism.PMID:38650100 | DOI:10.4093/dmj.2023.0277 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Tong Bu Ziyan Sun Yi Pan Xia Deng Guoyue Yuan Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
This article reviews the recent research progress of GLP-1 in lipid metabolism.PMID:38650100 | DOI:10.4093/dmj.2023.0277 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Tong Bu Ziyan Sun Yi Pan Xia Deng Guoyue Yuan Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
This article reviews the recent research progress of GLP-1 in lipid metabolism.PMID:38650100 | DOI:10.4093/dmj.2023.0277 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Tong Bu Ziyan Sun Yi Pan Xia Deng Guoyue Yuan Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
